Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
== Early life and legal career == Kerry-Lynne Findlay was born in 1955 in Ladysmith, British Columbia, and lived in Nanaimo and Victoria; her brother Greg Findlay was a linebacker for the BC Lions Canadian Football League (CFL) team. She comes from a family with many former CFL players; Findlay's father Stephen Findlay played for the Hamilton Tigers in the 23rd Grey Cup. After graduating from Crofton House School in Vancouver, she attended the University of British Columbia, receiving a Bachelor of Arts degree in history and political science in 1975, and a law degree in 1978. She articled at Kowarsky and Company in Vancouver, then worked there as an associate for two years before briefly serving as in-house counsel for the Insurance Corporation of British Columbia. She established her own practice in 1981, then joined Connell Lightbody in 1987 before switching to Watson Goepel Maledy in 1996. During her legal career, Findlay has been active in both the national and B.C. provincial branch of the Canadian Bar Association. She held various positions in that organization including national and provincial chair of the Constitutional Law Section and member of the National Task Force on Canadian Court Reform, and she was acclaimed president of the B.C. Branch for the 1997–1998 term. Findlay was appointed Queen's Counsel in March 1999 by the Attorney General of British Columbia, and served a five-year term as a Member of the Canadian Human Rights Tribunal by appointment of the Federal Minister of Justice (2006–2011).
==== Eyes ==== The eye can be directly affected in the form of episcleritis or scleritis, which, when severe, can very rarely progress to perforating scleromalacia. Rather more common is the indirect effect of keratoconjunctivitis sicca, which is a dryness of eyes and mouth caused by lymphocyte infiltration of lacrimal and salivary glands. When severe, dryness of the cornea can lead to keratitis and loss of vision, as well as being painful. Preventive treatment of severe dryness with measures such as nasolacrimal duct blockage is important.
== External links == Working Principle of Spring Check Valves Check Valves Tutorial The operation, benefits, applications and selection of different designs, including lift, disc, swing and wafer check valves are explained in this tutorial A picture of a microscopic checkvalve, a scaled down version of Tesla's original fluidic diode. US Patent 1,329,559, Tesla's original fluidic diode (a test of a design showing very poor performance – n.b. the test protocol did not match the conditions described in the patent) Check Valve Installation and Benefits
Sources: en.wikipedia.org
(1990); "Copper-Catalyzed Amino Acid Condensation in Water - A Simple Possible Way of Prebiotic Peptide Formation"; Origins Life Evol. Biosphere 1990, 20(5), pp. 401–410. DOI: 10.1007/BF01808134. Schwendinger, M. G.; Rode, Bend M.(1998); "Possible Role of Copper and Sodium Chloride in Prebiotic Evolution of Peptides"; Anal. Sci. 1989, 5(4), pp. 411–414. DOI: 10.2116/analsci.5.411. Plankensteiner, Kristof; Reiner, Hannes; Schranz, Benjamin; Rode, Bernd M. (2004); "Prebiotic formation of amino acids in a neutral atmosphere by electric discharge"; Angew. Chem. Int. Ed. 2004, 43, pp. 1886–1888. [1] Fitz, Daniel; Reiner, Hannes; Rode, Bernd M. (2007); "Chemical evolution toward the origin of life"]; Pure Appl. Chem. 2007, 79(12), pp. 2101–2117. DOI: 10.1351/pac200779122101. Fitz, Daniel; Jakschitz, Thomas; Rode, Bernd M. (2011); "Salt-Induced Peptide Formation in Chemical Evolution: Building Blocks Before RNA - Potential of Peptide Splicing Reactions"; In: Origins of Life: The Primal Self-Organization, Egel, Richard; Lankenau, Dirk-Henner; Mulkidjanian, Armen Y. (Eds.), ISBN 978-3-642-21624-4, Springer, Heidelberg, Berlin 2011, pp. 109–127. Jakschitz, Thomas A.; Rode, Bernd M. (2012); "Chemical Evolution from simple inorganic compounds to chiral peptides"; Chem. Soc. Rev. 2012, 41(16), pp. 5484–5489. DOI: 10.1039/C2CS35073D. Rode, Bernd M.; Plankensteiner, Kristof (2013); "Prebiotic Peptides"; In: Handbook of Biologically Active Peptides, Second Edition, Abba J. Kastin (Eds.), ISBN 978-012-3850959, Elsevier, Amsterdam 2013, pp. 1899–1903.
In late August 2013, Starbucks announced its first store in Colombia at a press conference in Bogotá, where the company's CEO explained, "Starbucks has always admired and respected Colombia's distinguished coffee tradition." In May 2014, Starbucks announced its first café in Bolivia would open in 2014 in Santa Cruz de la Sierra and the first in Panama in 2015. In January 2016, Starbucks announced that it would launch operation in Trinidad and Tobago. On August 29, 2016, Starbucks opened its first store at South Park Mall in San Fernando. In November 2017, Starbucks commenced operations in Jamaica, where the first store opened in the resort city of Montego Bay on the shores of the Doctor's Cave Beach Club, offering views of the Caribbean Sea. The company also reaffirmed its commitment to working with local coffee farmers to "implement systems to increase productivity and yields, while also increasing compliance to international standards". Starbucks Jamaica opened its first store on November 21, 2017, with plans to open 15 locations island-wide over a 5-year period. Starbucks Jamaica opened stores at the Sangster International Airport in Montego Bay and at the Falmouth Pier, in Falmouth, Jamaica. Starbucks Jamaica announced plans to open up to six stores in Kingston, Jamaica, by 2019. The first of the Kingston stores opened on June 21, 2018. The second store is in Kingston's central business district, New Kingston.
== Function == Gastrin-releasing peptide is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate bombesin/GRP neurons of the stomach release GRP, which stimulates the G cells to release gastrin. GRP is also involved in the biology of the circadian system, playing a role in the signaling of light to the master circadian oscillator in the suprachiasmatic nuclei of the hypothalamus. Furthermore, GRP seems to mediate certain aspects of stress. This is the reason for the observed fact that atropine does not block the vagal effect on gastrin release.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.